The firm posted revenues of $89 million driven by genetic analysis and product revenues, beating Wall Street estimates despite negative currency effects.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The lab has partnered with both WaferGen and Fluidigm to improve throughput for the barcode sequencing protocol it has developed for transcriptome profiling.
The partners will combine the sciFlexarrayer with Anteo's reagents to improve the functionality and shelf-life of activated glass and polymer slides and other arrays.
The developers of the method are now using the ddPCR approach to create and test assays for early colon cancer detection.
In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.
Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."
Ivan Oransky discusses the need for reproducibility research at The Conversation.
The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.